Catching the unseen
Supporting radiologists and clinicians worldwide in screening, early diagnosis & treatment of cancer
iBiopsy® becomes eyonis™
Catching the Unseen
Next generation end-to-end AI/ML tech-based CADe CADx Software as Medical Devices (SaMDs) with unprecedented performance
Our goal is to reduce cancers burdens by helping radiologists and clinicians identify disease at the earliest possible stage, allowing better care while avoiding unnecessary procedures and reducing healthcare costs.
With eyonis™, we are committed to improving patients’ lives with a portfolio of the most accurate AI/ML tech-based Software as Medical Devices (SaMDs) dedicated to early diagnosis of cancers.
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician.” A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease.” Source: FDA
Enabling the early detection & characterization of cancer to improve patients’ lives
Early and accurate diagnosis
Shorter time to treatment
Reduced disease burden and improved examination adherence
Decrease false positives and false negative results
Reduced image review time and intra & inter-operator variability
Increased patient compliance thanks to greater trust in diagnostic accuracy
Healthcare Organizations Benefits
Fewer procedures to reach final diagnosis
Reduced need for late-stage & costly drug treatments
Leveraging Median’s medical imaging expertise
Combining the power of AI & Data Science
eyonis™ provides a portfolio of innovative end-to-end AI/ML tech-based Software as Medical Devices (SaMDs) in indications where early diagnosis is an unmet need.
eyonis™’s goal is to shift the medical diagnostic paradigm, in Lung Cancer and Liver Cancer.
The power of eyonis™
Leveraging Median’s medical imaging expertise, combined with the power of AI & Data Science, eyonis™ brings the power to:
- Achieve unprecedented diagnostic accuracy
- Decrease false negative & false positive results
- Improve patients’ lives
- Optimize radiologist time
- Increase workflow standardization
- Reduce unnecessary procedures and healthcare spending
Lung Cancer Screening (LCS) and incidental pulmonary nodules (IPN)
Very early Hepatocellular Carcinoma (HCC)
Liver fibrosis in nonalcoholic steatohepatitis (NASH)
Median Technologies Announces Rebranding of iBiopsy®, Changes Name to eyonis™
Median Technologies unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD) and business unit.
Median Technologies to speak at the Radiological Society of North America 2023 Annual Meeting, Nov. 26 – 30, Chicago, IL, USA
AI Theater Presentation: “Transforming Cancer Diagnosis through End-to-End AI-Powered SaMD”
First results of Median Technologies’ iBiopsy® HCC detection AI model developed on the PHELICAR Clinical Data Registry, to be presented at the ESMO Congress(Oct 20-24, 2023, Madrid, Spain)
Median Technologies announces onboarding of all academic sites involved in the pivotal validation plan for iBiopsy® LCS CADe/CADx SaMD
Learn more about eyonis™
Our team welcomes you to explore further our unprecedented technology for diagnostic imaging.